Correlation Engine 2.0
Clear Search sequence regions


  • apoptosis (2)
  • cases (1)
  • malignant melanoma (9)
  • miR 125 (2)
  • MiR 125b (8)
  • NCAM (7)
  • NCAM 180 (2)
  • NCAM- 120 (2)
  • rnas (3)
  • Sizes of these terms reflect their relevance to your search.

    To investigate the effects of micro ribonucleic acid (miR)-125b on the growth and apoptosis of malignant melanoma (MM) cells and related mechanisms. The differences in the expressions of miR-125b and neural cell adhesion molecule-120 (NCAM-120), NCAM-140 and NCAM-180 in 5 cases of MM tissues (MM group) and corresponding adjacent tissues (Paracancer group) as well as MM cells were detected via quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry, respectively. Next, malignant melanoma A375 cells were selected to exogenously overexpress miR-125 (miR-125 mimic group). Then, in vitro functional assays were conducted to determine the influences of miR-125b on the proliferation, migration and apoptosis of MM cells, and the changes in the binding of miR-125b to the 3'-untranslated region (3'-UTR) of wild-type and mutant NCAM messenger RNAs (mRNAs) were verified using dual-luciferase assay. MiR-125b was significantly lowly expressed in MM tissues and cells (p<0.01), while NCAM-120, NCAM-140 and NCAM-180 were clearly highly expressed in MM tissues and cells (p<0.05). After miR-125b was exogenously overexpressed in A375 cells, the proliferation and migration ability of A375 cells was decreased, whereas the proportion of apoptotic cells rose (p<0.05). Besides, the results of dual-luciferase reporter assay revealed that the luciferase activity of A375 cells in the 3'-UTR of wild-type NCAM mRNA was overtly lowered compared with that of mutant NCAM mRNA (p<0.05). MiR-125b acts as a tumor suppressor in MM cells by targeting and binding to NCAM.

    Citation

    Tao Wang, Wei Li, Shuang Yin, Weihua Chen. MiR-125b acts as a tumor suppressor of melanoma by targeting NCAM. Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 2021 Jan-Feb;26(1):182-188


    PMID: 33721450

    View Full Text